PDF herunterladen
CC BY 4.0 · Rev Bras Ginecol Obstet 2023; 45(01): 043-048
DOI: 10.1055/s-0042-1759631
Review Article | Artigo de Revisão

Corifollitropin Alfa for Controlled Ovarian Stimulation in Assisted Reproductive Technologies: State of the Art

Alfacorifolitropina para estimulação ovariana controlada em tecnologias de reprodução assistida: Estado da arte
Bruno Ramalho de Carvalho 
1   Bruno Ramalho Reprodução Humana, Brasília, DF, Brazil
› Institutsangaben
› Weitere Informationen
  Lizenzen und Reprints

Abstract

Physical and emotional burdens during the journey of infertile people through assisted reproductive technologies are sufficient to justify the efforts in developing patient-friendly treatment strategies. Thus, shorter duration of ovarian stimulation protocols and the need for less injections may improve adherence, prevent mistakes, and reduce financial costs. Therefore, the sustained follicle-stimulating action of corifollitropin alfa may be the most differentiating pharmacokinetic characteristic among available gonadotropins. In this paper, we gather the evidence on its use, aiming to provide the information needed for considering it as a first choice when a patient-friendly strategy is desired.

Resumo

O desgaste físico e emocional durante a jornada de pessoas inférteis pelas tecnologias de reprodução assistida é suficiente para justificar esforços no desenvolvimento de estratégias de tratamento compassivas. Desta forma, a menor duração dos protocolos de estimulação ovariana e a necessidade de menos injeções podem melhorar a adesão, prevenir erros e reduzir custos financeiros. Portanto, a estimulação folicular sustentada da alfacorifolitropina parece ser a característica farmacocinética que melhor a diferencia das gonadotrofinas atualmente disponíveis no mercado. No presente artigo, reunimos evidências sobre seu uso, com o objetivo de fornecer as informações necessárias para considerá-la como primeira escolha quando se deseja uma estratégia amigável ao paciente.

Keywords

corifollitropin alfa - ovulation induction - ovarian stimulation - gnrh antagonist - assisted fertilization

Palavras-chave

alfacorifolitropina - indução de ovulação - estimulação ovariana - antagonista de gnrh - reprodução assistida


Publikationsverlauf

Eingereicht: 06. April 2022

Angenommen: 27. August 2022

Artikel online veröffentlicht:
06. März 2023

© 2023. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Gameiro S, Boivin J, Peronace L, Verhaak CM. Why do patients discontinue fertility treatment? A systematic review of reasons and predictors of discontinuation in fertility treatment. Hum Reprod Update 2012; 18 (06) 652-669
    CrossrefPubMedSuche in Google Scholar
  • 2 Verberg MF, Eijkemans MJ, Heijnen EM, Broekmans FJ, de Klerk C, Fauser BCJM. et al. Why do couples drop-out from IVF treatment? A prospective cohort study. Hum Reprod 2008; 23 (09) 2050-2055
    CrossrefPubMedSuche in Google Scholar
  • 3 Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC. ENGAGE Investigators. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 2009; 24 (12) 3063-3072
    CrossrefPubMedSuche in Google Scholar
  • 4 Barrenetxea G, García-Velasco JA, Aragón B. et al. Comparative economic study of the use of corifollitropin alfa and daily rFSH for controlled ovarian stimulation in older patients: Cost-minimization analysis based on the PURSUE study. Reprod Biomed Soc Online 2018; 5: 46-59
    CrossrefPubMedSuche in Google Scholar
  • 5 Corifollitropin alfa Ensure Study Group. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight women. Reprod Biomed Online 2010; 21 (01) 66-76
    CrossrefPubMedSuche in Google Scholar
  • 6 Mardešič T, Mannaerts B, Abuzeid M, Levy M, Witjes H, Fauser BC. Engage investigators. Short follicular phase of stimulation following corifollitropin alfa or daily recombinant FSH treatment does not compromise clinical outcome: a retrospective analysis of the Engage trial. Reprod Biomed Online 2014; 28 (04) 462-468
    CrossrefPubMedSuche in Google Scholar
  • 7 Norman RJ, Zegers-Hochschild F, Salle BS, Elbers J, Heijnen E, Marintcheva-Petrova M. et al; Trust Investigators. Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity. Hum Reprod 2011; 26 (08) 2200-2208
    CrossrefPubMedSuche in Google Scholar
  • 8 Boostanfar R, Mannaerts B, Pang S, Fernandez-Sanchez M, Witjes H, Devroey P. Engage Investigators. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle-stimulating hormone. Fertil Steril 2012; 97 (06) 1351-1358
    CrossrefPubMedSuche in Google Scholar
  • 9 Cozzolino M, Vitagliano A, Cecchino GN, Ambrosini G, Garcia-Velasco JA. Corifollitropin alfa for ovarian stimulation in in vitro fertilization: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2019; 111 (04) 722-733
    CrossrefPubMedSuche in Google Scholar
  • 10 Pouwer AW, Farquhar C, Kremer JA. Long-acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database Syst Rev 2015; (07) CD009577
    CrossrefPubMedSuche in Google Scholar
  • 11 Griesinger G, Boostanfar R, Gordon K, Gates D, McCrary Sisk C, Stegmann BJ. Corifollitropin alfa versus recombinant follicle-stimulating hormone: an individual patient data meta-analysis. Reprod Biomed Online 2016; 33 (01) 56-60
    CrossrefPubMedSuche in Google Scholar
  • 12 Boostanfar R, Shapiro B, Levy M, Rosenwaks Z, Witjes H, Stegmann BJ. et al; Pursue investigators. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization. Fertil Steril 2015; 104 (01) 94-103.e1
    CrossrefPubMedSuche in Google Scholar
  • 13 Bonduelle M, Mannaerts B, Leader A, Bergh C, Passier D, Devroey P. Prospective follow-up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Hum Reprod 2012; 27 (07) 2177-2185
    CrossrefPubMedSuche in Google Scholar
  • 14 Tarlatzis BC, Griesinger G, Leader A, Rombauts L, Ijzerman-Boon PC, Mannaerts BM. Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH. Reprod Biomed Online 2012; 24 (04) 410-419
    CrossrefPubMedSuche in Google Scholar
  • 15 Griesinger G, Verweij PJ, Gates D, Devroey P, Gordon K, Stegmann BJ. et al. Prediction of ovarian hyperstimulation syndrome in patients treated with corifollitropin alfa or rFSH in a GnRH antagonist protocol. PLoS One 2016; 11 (03) e0149615
    CrossrefPubMedSuche in Google Scholar
  • 16 Lawrenz B, Beligotti F, Engelmann N, Gates D, Fatemi HM. Impact of gonadotropin type on progesterone elevation during ovarian stimulation in GnRH antagonist cycles. Hum Reprod 2016; 31 (11) 2554-2560
    CrossrefPubMedSuche in Google Scholar
  • 17 Leader A, Devroey P, Witjes H, Gordon K. Corifollitropin alfa or rFSH treatment flexibility options for controlled ovarian stimulation: a post hoc analysis of the Engage trial. Reprod Biol Endocrinol 2013; 11: 52
    CrossrefPubMedSuche in Google Scholar
  • 18 Blockeel C, Polyzos NP, Derksen L, De Brucker M, Vloeberghs V, van de Vijver A. et al. Administration of corifollitropin alfa on Day 2 versus Day 4 of the cycle in a GnRH antagonist protocol: a randomized controlled pilot study. Hum Reprod 2014; 29 (07) 1500-1507
    CrossrefPubMedSuche in Google Scholar
  • 19 Revelli A, Gennarelli G, Sestero M, Canosa S, Carosso A, Salvagno F. et al. A prospective randomized trial comparing corifollitropin-α late-start (day 4) versus standard administration (day 2) in expected poor, normal, and high responders undergoing controlled ovarian stimulation for IVF. J Assist Reprod Genet 2020; 37 (05) 1163-1170
    CrossrefPubMedSuche in Google Scholar
  • 20 Drakopoulos P, Vuong TNL, Ho NAV, Vaiarelli A, Ho MT, Blockeel C. et al. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial. Hum Reprod 2017; 32 (11) 2225-2233
    CrossrefPubMedSuche in Google Scholar
  • 21 Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L. ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011; 26 (07) 1616-1624
    CrossrefPubMedSuche in Google Scholar
  • 22 Decleer W, Comhaire F, Balduyck J, Ameye A, Osmanagaoglu K, Devroey P. Replacing HMG/FSH by low-dose HCG to complete corifollitropin alfa stimulation reduces cost per clinical pregnancy: a randomized pragmatic trial. Reprod Biomed Online 2020; 40 (03) 468-474
    CrossrefPubMedSuche in Google Scholar
  • 23 Fatemi HM, Oberyé J, Popovic-Todorovic B, Witjes H, Mannaerts B, Devroey P. Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trial. Fertil Steril 2010; 94 (05) 1922-1924
    CrossrefPubMedSuche in Google Scholar
  • 24 Kolibianakis EM, Venetis CA, Bosdou JK, Zepiridis L, Chatzimeletiou K, Makedos A. et al. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial. Hum Reprod 2015; 30 (02) 432-440
    CrossrefPubMedSuche in Google Scholar
  • 25 Taronger R, Martínez-Cuenca S, Ferreros I, Rubio JM, Fernández-Colom PJ, Martínez-Triguero ML. et al. Ovarian stimulation with corifollitropin alfa followed by hp-hMG compared to hp-hMG in patients at risk of poor ovarian response undergoing ICSI: A randomized controlled trial. Eur J Obstet Gynecol Reprod Biol 2018; 231: 192-197
    CrossrefPubMedSuche in Google Scholar
  • 26 Fusi FM, Zanga L, Arnoldi M, Melis S, Cappato M, Candeloro I. et al. Corifollitropin alfa for poor responders patients, a prospective randomized study. Reprod Biol Endocrinol 2020; 18 (01) 67
    CrossrefPubMedSuche in Google Scholar
  • 27 Corifollitropin Alfa Dose-finding Study Group. A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Hum Reprod 2008; 23 (11) 2484-2492
    CrossrefPubMedSuche in Google Scholar
  • 28 Zandvliet AS, Prohn M, de Greef R, van Aarle F, McCrary Sisk C, Stegmann BJ. Impact of patient characteristics on the pharmacokinetics of corifollitropin alfa during controlled ovarian stimulation. Br J Clin Pharmacol 2016; 82 (01) 74-82
    CrossrefPubMedSuche in Google Scholar
  • 29 Vuong NL, Pham DT, Phung HT, Giang HN, Huynh GB, Nguyen TTL. et al. Corifollitropin alfa vs recombinant FSH for controlled ovarian stimulation in women aged 35-42 years with a body weight ≥50 kg: a randomized controlled trial. Hum Reprod Open 2017; 2017 (03) hox023
    CrossrefPubMedSuche in Google Scholar
  • 30 Cruz M, Alamá P, Muñoz M, Collado D, Blanes C, Solbes E. et al. Economic impact of ovarian stimulation with corifollitropin alfa versus conventional daily gonadotropins in oocyte donors: a randomized study. Reprod Biomed Online 2017; 34 (06) 605-610
    CrossrefPubMedSuche in Google Scholar
  • 31 Khoa LD, Lan VTN, Loc NMT, Vinh DQ, Tran QN, Tuong HM. Corifollitropin alfa versus follitropin beta: an economic analysis alongside a randomized controlled trial in women undergoing IVF/ICSI. Reprod Biomed Soc Online 2020; 10: 28-36
    CrossrefPubMedSuche in Google Scholar
  • 32 Requena A, Cruz M, Collado D, Izquierdo A, Ballesteros A, Muñoz M. et al. Evaluation of the degree of satisfaction in oocyte donors using sustained-release FSH corifollitropin α. Reprod Biomed Online 2013; 26 (03) 253-259
    CrossrefPubMedSuche in Google Scholar
  • 33 Huang CY, Chen GY, Shieh ML, Li HY. An extremely patient-friendly and efficient stimulation protocol for assisted reproductive technology in normal and high responders. Reprod Biol Endocrinol 2018; 16 (01) 18
    CrossrefPubMedSuche in Google Scholar
  • 34 Huang CY, Chen GY, Shieh ML, Li HY. Validating the use of corifollitropin alfa in progestin-primed ovarian stimulation protocol on normal and high responders by comparing with conventional antagonist protocol: a retrospective study. Life (Basel) 2020; 10 (06) 90
    CrossrefPubMedSuche in Google Scholar
  • 35 Yu S, Long H, Chang HY, Liu Y, Gao H, Zhu J. et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod 2018; 33 (02) 229-237
    CrossrefPubMedSuche in Google Scholar
  • 36 Huang TC, Huang MZ, Seow KM, Yang I-J, Pan S-P, Chen M-J. et al. Progestin primed ovarian stimulation using corifollitropin alfa in PCOS women effectively prevents LH surge and reduces injection burden compared to GnRH antagonist protocol. Sci Rep 2021; 11 (01) 22732
    CrossrefPubMedSuche in Google Scholar
  • 37 Hwang JL, Chen SU, Chen HJ, Chen H-F, Yang Y-S, Chang C-H. et al. Feasibility of corifollitropin alfa/GnRH antagonist protocol combined with GnRH agonist triggering and freeze-all strategy in polycystic ovary syndrome patients. J Formos Med Assoc 2018; 117 (06) 535-540
    CrossrefPubMedSuche in Google Scholar